2 documents found, page 1 of 1

Sort by Issue Date

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine ...

Almeida, Antonio; Pierdomenico, Francesca; Guerrero, Blanca Polo; Saraiva, Filipa; Montalvão, Ana; Coutinho, Jorge; Mariz, Mário; Melo, Teresa

Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment. However, currently, the treatment-free remission concept is becoming an important goal in clinical practice, and several tyrosine kinase inhibitors discontinuation studies have shown that  round 50% of patients with a durable deep molecular response beyond majo...

Date: 2019   |   Origin: Acta Médica Portuguesa

Negative MR4·0 chronic myeloid leukaemia and its possible implications for trea...

Cerveira, Nuno; Diamond, Joana; Matos, Sónia; Amorim, Maria L; Coucelo, Margarida; Bizarro, Susana; Simões, Ana Teresa; Pierdomenico, Francesca

ABL1 tyrosine kinase inhibitors (TKI) have dramatically improved the outcome for chronic myeloid leukaemia (CML) patients, resulting in a life expectancy that approaches that of the general population. Nevertheless, lifelong TKI therapy may have consequences, including chronic adverse events that can substantially impact patients’ quality of life, adherence to therapy and treatment success. Recently, several cl...


2 Results

Queried text

Refine Results

Author





















Date


Document Type


Access rights


Resource



Subject